Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

"DAAN Biotherapeutics and GC Cell agree on CAR-T, CAR-NK therapies" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million). The French pharma is buying ...

Natural killer (NK) cells are innate immune lymphocytes that play a crucial role in tumor surveillance and control. In recent years, NK cell-based therapies for cancer have garnered significant ...

We investigated the ability of PARP inhibitors (PARPi) to induce senescence of fibroblasts and its impact on the proliferation of PCa cell lines and NK cell-mediated cytotoxicity. Methods: Senescence ...

and chimeric antigen receptor natural killer cell (CAR-NK) therapy research and development. This antibody is said to target a tumour antigen prevalent in several major solid cancers such as ...

OT-C001 is an allogeneic cell therapy of highly activated and expanded NK cells from UCB, manufactured using a patented expansion and activation process. It targets tumor cells through direct and ...

There are several types—called T cells, B cells, and natural killer (NK) cells—that support the immune system in different ways. The main function of lymphocytes is to recognize and neutralize foreign ...